Trutek Corp. v. BlueWillow Biologics, Inc.

CourtDistrict Court, E.D. Michigan
DecidedNovember 17, 2022
Docket4:21-cv-10312
StatusUnknown

This text of Trutek Corp. v. BlueWillow Biologics, Inc. (Trutek Corp. v. BlueWillow Biologics, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Michigan primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Trutek Corp. v. BlueWillow Biologics, Inc., (E.D. Mich. 2022).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION

TRUTEK CORP., Case No. 2:21-cv-10312 Plaintiff/Counter-Defendant, HONORABLE STEPHEN J. MURPHY, III v.

BLUEWILLOW BIOLOGICS, INC.,

Defendant/Counter-Plaintiff. /

OPINION AND ORDER DENYING MOTION FOR LEAVE TO AMEND COMPLAINT [44]

Plaintiff sued Defendant for patent infringement. ECF 1, PgID 6. Defendant denied Plaintiff’s allegations. ECF 9, PgID 84. After the parties submitted briefing for a claim construction hearing, Plaintiff moved to amend the complaint and add a claim of willful patent infringement. ECF 44. The parties briefed the motion. ECF 47; 48. For the reasons below, the Court will deny the motion.1 BACKGROUND The United States Patent and Trademark Office assigned Plaintiff United States Patent Number 8,163,802 (the ’802 patent). ECF 1, PgID 2–3. The patented technology allows consumers to apply Plaintiff’s “products in and around their nasal passages to reduce reactions to airborne allergens and to reduce or eliminate reactions to viral infections” such as the flu. Id. at 3. Plaintiff’s technology eliminates

1 Based on the parties’ briefing, the Court will resolve the motion on the briefs without a hearing. See Fed. R. Civ. P. 78(b); E.D. Mich. L.R. 7.1(f)(2). viruses “by establishing an electrostatic charge in and around nasal passages.” Id. Defendant sells a product called NanoBio Protect. ECF 1, PgID 4; ECF 9, PgID 72. The product is also applied to the nasal passages and “kill[s]” germs. ECF 1, PgID 4.

Plaintiff sued Defendant for patent infringement and alleged that Defendant’s product infringed on Plaintiff’s ’802 patent because “[t]he ability to lessen the reactions to airborne contaminants by creating an electrostatic charge around a person’s nasal passages is inherent in [Plaintiff]’s formulations and manufacturing processes.” Id. at 6. Plaintiff argued that Defendant’s product uses benzalkonium chloride, the same substance Plaintiff uses in its product. Id. at 4, 7. Defendant

denied Plaintiff’s allegations, and argued that the ’802 patent was “invalid and has not been . . . infringed by [Defendant].” ECF 9, PgID 84. After the close of discovery, Plaintiff moved to amend its complaint to add a claim of willful patent infringement. ECF 44. Plaintiff argued that it had not learned of the need for an amendment until Defendant produced its financial disclosures one month after the close of discovery. Id. at 799. In its proposed amended complaint, Plaintiff alleged that Defendant had “received notice” that its product infringed

Plaintiff’s patent “when Plaintiff filed the original complain[t].” ECF 44-1, PgID 819. Yet Defendant “continued to market, distribute, and sell NANOBIO products for months after learning that the NANOBIO products infringed on claims 1, 2, 6[,] and 7 of the ’802 patent.” Id. at 823. Defendant’s financial records, maintained Plaintiff, established “by a preponderance of the evidence that enhanced damages [were] appropriate.” Id. at 819. Plaintiff requested that Defendant be required to pay Plaintiff for all gains it derived from the infringement of the ’802 patent. Id. at 824. LEGAL STANDARD

Federal Rule of Civil Procedure 15(a)(2) provides that after a responsive pleading is filed and twenty-one days has elapsed, a party may only amend a pleading with the written consent of the opposing party or with leave of the Court. Rule 15(a)(2) also provides that “[t]he [C]ourt should freely give leave when justice so requires.” See also Foman v. Davis, 371 U.S. 178, 182 (1962). To determine whether to grant leave to amend a pleading, the Court relies on six factors: (1) “undue delay in filing”;

(2) “lack of notice to the opposing party”; (3) “bad faith by the moving party”; (4) “repeated failure to cure deficiencies by previous amendments”; (5) “undue prejudice to the opposing party”; and (6) “futility of [the] amendment.” Wade v. Knoxville Utils. Bd., 259 F.3d 452, 458–59 (6th Cir. 2001) (quotation omitted). DISCUSSION Plaintiff moved for leave to amend its complaint to add a claim of willful patent infringement. ECF 44. The Court will deny the motion based on three of the factors:

undue delay, undue prejudice to Defendant, and futility of the amendment. I. Undue Delay The Court will first deny the motion for leave to amend the complaint because of Plaintiff’s “undue delay in filing.” Wade, 259 F.3d at 458. There is “an increased burden” on a party that moves to amend a complaint after the close of the discovery. Duggins v. Steak ‘N Shake, Inc., 195 F.3d 828, 834 (6th Cir. 1999) (citation omitted). The moving party must “show justification for the failure to move earlier.” Id. In short, Plaintiff offered little to no justification for waiting to move for leave to amend at the present late point in the litigation. Indeed, Plaintiff’s motion was filed more

than five months after the close of discovery and less than a month before the close of expert discovery.2 See Bridgeport Music, Inc. v. Dimension Films, 410 F.3d 792, 806–07 (6th Cir. 2005) (affirming a district court’s denial of leave to amend a complaint with only a few weeks left in discovery); R.S.W.W., Inc. v. City of Keego Harbor, 397 F.3d 427, 440–41 (6th Cir. 2005) (affirming a district court’s denial of leave to amend a complaint after the close of discovery). And Plaintiff could have

easily discovered Defendant’s knowledge of its alleged willful infringement in other ways. For instance, Plaintiff could have searched for Defendant’s product online or at a local pharmacy as it had done before the case was filed. ECF 44-1, PgID 849–55; ECF 1-5, PgID 32–33. Yet Plaintiff did not explain that it had not taken any such action before filing the previous complaint. See Scott v. Hemlock Semiconductor Corp., No. 06-14903, 2007 WL 2649360, at *3 (E.D. Mich. Sept. 10, 2007) (denying motion to amend because no explanation was given for why a claim was not brought in the

previously filed complaint). Instead, Plaintiff argued that its delay in filing the present motion was not undue because it was based on information contained in Defendant’s financial records, which were not provided to Plaintiff until one month after the close of

2 Discovery closed on May 16, 2022. ECF 26. Plaintiff filed its motion for leave to amend on October 25, 2022. ECF 44. Expert discovery closed on November 14, 2022. ECF 26. discovery.3 ECF 44, PgID 799–800; ECF 47, PgID 909; ECF 48, PgID 932. Plaintiff blamed Defendant for the “delayed” disclosure, which in turn caused Plaintiff to not “have the opportunity to scrutinize details regarding the sales of the Nano[B]io

product” until after the close of discovery. ECF 44, PgID 807. Plaintiff is correct that Defendant did not provide the financial records until one month after the close of fact discovery.4 But Plaintiff delayed another four months to file the present motion. Compared with Defendant’s one-month delay, Plaintiff’s four-month delay was undue. The factor thus cuts against granting Plaintiff’s motion for leave to amend. II. Prejudice

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Trutek Corp. v. BlueWillow Biologics, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/trutek-corp-v-bluewillow-biologics-inc-mied-2022.